Mary L Disis Selected Research

Toll-Like Receptors (Toll-Like Receptor)

7/2017	Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
5/2017	Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary L Disis Research Topics

Disease

132	Neoplasms (Cancer) 01/2023 - 01/2002
61	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2002
21	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 06/2002
5	Triple Negative Breast Neoplasms 01/2021 - 08/2015
5	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2005
5	Carcinoma (Carcinomatosis) 12/2013 - 04/2006
4	Carcinogenesis 05/2021 - 08/2014
4	Human Influenza (Influenza) 01/2017 - 05/2002
4	Inflammation (Inflammations) 01/2017 - 11/2009
3	Colonic Neoplasms (Colon Cancer) 10/2022 - 01/2021
3	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 01/2003
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 02/2007
3	Disease Progression 01/2019 - 07/2006
3	Squamous Cell Carcinoma of Head and Neck 05/2017 - 01/2016
3	Hypersensitivity (Allergy) 12/2009 - 07/2002
2	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2022 - 05/2021
2	Melanoma (Melanoma, Malignant) 12/2020 - 01/2015
2	Lung Neoplasms (Lung Cancer) 01/2019 - 11/2016
2	Infections 02/2017 - 04/2015
2	Glioblastoma (Glioblastoma Multiforme) 02/2017 - 07/2003
2	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 02/2016
2	Communicable Diseases (Infectious Diseases) 01/2017 - 04/2008
2	Obesity 01/2017 - 06/2013
2	Neoplasm Micrometastasis 12/2013 - 03/2012
2	Testicular Neoplasms (Testicular Cancer) 10/2005 - 09/2005
1	Endometrial Neoplasms (Endometrial Cancer) 01/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2023
1	Prostatic Intraepithelial Neoplasia 10/2022
1	Body Weight (Weight, Body) 10/2022

Drug/Important Bio-Agent (IBA)

50	AntigensIBA 10/2022 - 01/2002
48	VaccinesIBA 01/2023 - 03/2002
38	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2002
23	Peptides (Polypeptides)IBA 01/2022 - 04/2002
20	Neoplasm Antigens (Tumor Antigens)IBA 05/2021 - 06/2002
19	EpitopesIBA 01/2022 - 07/2002
17	Biomarkers (Surrogate Marker)IBA 12/2018 - 02/2007
14	CytokinesIBA 12/2021 - 03/2002
12	Cancer VaccinesIBA 04/2017 - 10/2005
10	AntibodiesIBA 01/2020 - 03/2003
9	Immunoglobulin G (IgG)IBA 05/2021 - 03/2003
8	Immune Checkpoint InhibitorsIBA 01/2023 - 10/2014
7	Insulin-Like Growth Factor Binding Protein 2IBA 12/2021 - 05/2008
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 05/2002
6	AutoantibodiesIBA 05/2021 - 04/2008
5	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2005
4	Protein Subunit VaccinesIBA 01/2022 - 07/2002
4	Estrogen ReceptorsIBA 01/2022 - 10/2006
4	Insulin-Like PeptidesIBA 12/2021 - 06/2008
4	LigandsIBA 01/2021 - 10/2005
4	Monoclonal AntibodiesIBA 01/2016 - 02/2004
4	HLA-DR Antigens (HLA-DR)IBA 02/2010 - 01/2006
4	EnzymesIBA 02/2010 - 03/2002
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2016
3	InterferonsIBA 01/2022 - 06/2009
3	human ERBB2 proteinIBA 01/2022 - 10/2009
3	PlatinumIBA 01/2021 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 11/2006
3	VTX-2337IBA 01/2018 - 01/2016
3	Imiquimod (Aldara)FDA LinkGeneric 07/2017 - 05/2010
3	Oncogene Proteins (Oncogene Protein)IBA 11/2016 - 01/2005
3	Hormones (Hormone)IBA 10/2016 - 06/2013
3	Interleukin-2 (IL2)IBA 01/2016 - 07/2006
3	ChitosanIBA 02/2014 - 08/2010
3	AlginatesIBA 02/2014 - 08/2010
3	ImmunosorbentsIBA 02/2010 - 05/2002
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2003 - 05/2002
2	AzoxymethaneIBA 10/2022 - 01/2021
2	Dextrans (Dextran)FDA Link 10/2022 - 01/2006
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 01/2020
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 08/2013
2	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 02/2014
2	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2006
2	Phenobarbital (Luminal)FDA Link 01/2020 - 01/2017
2	Complementary DNA (cDNA)IBA 12/2019 - 03/2003
2	Indicators and Reagents (Reagents)IBA 01/2019 - 02/2006
2	ChemokinesIBA 01/2019 - 02/2014
2	CarcinogensIBA 01/2019 - 12/2014
2	Tumor Biomarkers (Tumor Markers)IBA 12/2018 - 09/2011
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2017 - 05/2017
2	Albumin-Bound Paclitaxel FDA Link 07/2017 - 01/2017
2	130-nm albumin-bound paclitaxelIBA 07/2017 - 01/2017
2	Cetuximab (Erbitux)FDA Link 05/2017 - 01/2016
2	Toll-Like Receptor AgonistsIBA 05/2017 - 05/2010
2	AutoantigensIBA 01/2017 - 10/2014
2	Interleukin-12 (IL 12)IBA 01/2016 - 05/2007
2	polysaccharide-KIBA 08/2013 - 01/2011
2	Trastuzumab (Herceptin)FDA Link 11/2011 - 10/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2010 - 05/2007
2	Transforming Growth Factor beta (TGF-beta)IBA 11/2009 - 10/2009
2	flt3 ligand protein (flt3 ligand)IBA 01/2003 - 04/2002
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 10/2022
1	Dihydrotachysterol (AT 10)IBA 10/2022
1	CycasinIBA 10/2022
1	epacadostatIBA 01/2022

Therapy/Procedure

37	Therapeutics 02/2022 - 01/2002
36	Immunotherapy 01/2023 - 01/2002
10	Drug Therapy (Chemotherapy) 02/2022 - 01/2004
6	Biological Therapy 09/2011 - 03/2002
5	Chemoprevention 01/2022 - 04/2010
4	Immunomodulation 02/2018 - 10/2008